DXB ASX Chart
Snapshot
Dimerix Limited (DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.
Share Price Activity (ASX)
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
Performance
1 Week | |
1 Month | |
2024 YTD | |
1 Year | |
vs Sector (1yr) | +206.18% |
vs ASX 200 (1yr) | +195.33% |
Latest Dimerix Ltd News
Announcements
Corporate Overview
Corporate Details
Head Office | Fitzroy VIC 3065 |
Website | www.dimerix.com |
Registry | Automic Group |
Auditor | Stantons |
Date Listed | 4 Feb 1993 |
Upcoming Calendar (Forecasted)
Date | Event |
---|---|
28/08/2024 | Report (Prelim) |
28/08/2024 | Report (Annual) |
24/02/2025 | Report (Interim) |
Former Company Names
- Sun Biomedical Limited (SBN), 30/11/2015
- Harrington Group Limited (HGR), 18/12/2007
- Ausfor Limited (ASF), 09/05/1997
- Pine Forests of Australia [Orange] Limited, 06/12/1988
Sponsored Financial Content
Dividend History
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
Directors & Management
Directors
Management
Director Transactions
DXB directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
Director Interests
The current holdings of DXB directors.
Shareholder Info
Substantial Shareholders
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Note: If a substantial shareholder's stake drops below 5%, the "Shareholders Selling" field shows full ownership as sold and sets "New %" to zero, even if they continue to hold shares under the limit.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
Mr Peter Meurs | 20/03/2024 | 75,304,506 | 13.80 |
Shareholders Buying
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
20-03-24 | Mr Peter Meurs | 5,928,514 | 15.09 | 13.80 |
12-03-24 | Mr Peter Meurs | 4,446,552 | 16.74 | 15.09 |
05-06-23 | Mr Peter Meurs | 20,750,131 | 13.77 | 16.74 |
Shareholders Selling
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
Historical Data
Share Price History
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Historical Data
Year | Closing Price | Last Trade |
---|---|---|
2023 | $0.062 | 30 June |
2022 | $0.120 | 30 June |
2021 | $0.195 | 30 June |
2020 | $0.350 | 30 June |
2019 | $0.085 | 28 June |
2018 | $0.095 | 29 June |
2017 | $0.010 | 28 June |
2016 | $0.007 | 28 June |
Important note:
All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits)
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.